Sirnaomics has announced the establishment of a strategic partnership with EDIRNA Inc. ("EDIRNA"), providing an initial funding and an exclusive licensing of Sirnaomics proprietary delivery technologies for advancing EDIRNA's proprietary "Edit-to-Cure TherapeuticsTM" platform, targeting diseases with high unmet clinical need.